Targeted sequencing of MCL tissues and ctDNA reveals predictors of outcome and response. (A) Schematic study design and DNA samples analyzed with targeted sequencing. cfDNA analyzed at baseline (BL) and after 6 cycles. (B) Oncoprint of 58 patients (columns) showing most recurrently mutated genes (rows) in the MCL genotypes. Coding mutations considered. (C) Dot and line graphs showing VAF (y-axis, logarithmic scale) of select variants in 2 patients in different hematologic compartments (x-axis) at BL. Below the graphs, fish plots of the estimated clonal architecture. Gray boxes indicate expected VAFs of MCL variants according to FC results in PB and BM samples. (D) Kaplan-Meier survival estimate according to TP53 mutations for PFS. (E) Kaplan-Meier survival estimate according to SMARCA4 mutations for PFS. (F) Forest plots of Cox proportional hazards models variables, 95% confidence intervals, and P values for multivariable models for PFS according to TP53 and SMARCA4 mutation statuses and with MIPI and number of previous treatment lines received. LDH, lactate dehydrogenase; LN, lymph node; MUT, mutation; PD, progressive disease; PR, partial response; WBC, white blood cell; WT, wild-type.